Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective

被引:17
作者
Yoon, Yeong Keng [1 ]
Oon, Chern Ein [1 ]
机构
[1] Univ Sains Malaysia, Inst Res Mol Med, Minden 11800, Penang, Malaysia
关键词
Histone deacetylases; sirtuin; inhibitor; epigenetic; cancer; NF-KAPPA-B; SMALL-MOLECULE INHIBITOR; NAD(+)-DEPENDENT HISTONE DEACETYLASES; STRESS-RESPONSIVE DEACETYLASE; EPSILON-THIOACETYL-LYSINE; FATTY-ACID OXIDATION; TUMOR-CELL GROWTH; SELECTIVE INHIBITORS; CAMBINOL ANALOGS; SIR2; HOMOLOG;
D O I
10.2174/1871520616666160310141622
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of sirtuins in age-related diseases is an area of rapidly expanding investigation. Sirtuins are NAD(+) -dependent class III histone deacetylases (HDACs) that share extensive homologies with the yeast HDAC Sir2. Class I and class II HDACs inhibitors have been identified as potential anticancer agents and are in clinical studies, but much less is known about class III HDAC inhibitors. However, inhibitors of sirtuins are currently being targeted as potential therapeutic agents for disease such as cancer, neurodegenerative disease and other disorders as sirtuins are discovered to regulate numerous downstream enzymes. Given the link between sirtuins and cancer, understanding the functionality of these enzymes may ultimately have significant impact in cancer prevention or cancer treatment. This review gives an updated overview regarding the regulation of sirtuin enzymes, their implications in cancer, various sirtuin inhibitor scaffolds and their insights in drug design.
引用
收藏
页码:1003 / 1016
页数:14
相关论文
共 175 条
[1]   Sirtuin-3 (SIRT3), a Novel Potential Therapeutic Target for Oral Cancer [J].
Alhazzazi, Turki Y. ;
Kamarajan, Pachiyappan ;
Joo, Nam ;
Huang, Jing-Yi ;
Verdin, Eric ;
D'Silva, Nisha J. ;
Kapila, Yvonne L. .
CANCER, 2011, 117 (08) :1670-1678
[2]   SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways [J].
Allison, Simon J. ;
Milner, Jo .
CELL CYCLE, 2007, 6 (21) :2669-2677
[3]   Altered sirtuin expression is associated with node-positive breast cancer [J].
Ashraf, N. ;
Zino, S. ;
MacIntyre, A. ;
Kingsmore, D. ;
Payne, A. P. ;
George, W. D. ;
Shiels, P. G. .
BRITISH JOURNAL OF CANCER, 2006, 95 (08) :1056-1061
[4]   Identification of a small molecule inhibitor of Sir2p [J].
Bedalov, A ;
Gatbonton, T ;
Irvine, WP ;
Gottschling, DE ;
Simon, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) :15113-15118
[5]   SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production [J].
Bell, E. L. ;
Emerling, B. M. ;
Ricoult, S. J. H. ;
Guarente, L. .
ONCOGENE, 2011, 30 (26) :2986-2996
[6]   Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators [J].
Bemis, Jean E. ;
Vu, Chi B. ;
Xie, Roger ;
Nunes, Joseph J. ;
Ng, Pui Yee ;
Disch, Jeremy S. ;
Milne, Jill C. ;
Carney, David P. ;
Lynch, Amy V. ;
Jin, Lei ;
Smith, Jesse J. ;
Lavu, Siva ;
Iffland, Andre ;
Jirousek, Michael R. ;
Perni, Robert B. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (08) :2350-2353
[7]   A stress response pathway involving sirtuins, forkheads and 14-3-3 proteins [J].
Berdichevsky, Ala ;
Guarente, Leonard .
CELL CYCLE, 2006, 5 (22) :2588-2591
[8]   Inside HDAC with HDAC inhibitors [J].
Bertrand, Philippe .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (06) :2095-2116
[9]   Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies [J].
Bhalla, KN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3971-3993
[10]   Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1 [J].
Bitterman, KJ ;
Anderson, RM ;
Cohen, HY ;
Latorre-Esteves, M ;
Sinclair, DA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (47) :45099-45107